RxDoctor Payments Data

Daniel Rasor, MD

Family Medicine · Austin, TXNPI 1043211329

Payments from drug & device makers

$16,532in general payments, 2019–2025

Across 754 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$2K
  • AbbVie$2K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • plus $7K from 44 others

What the payments were for

  • Food & beverage$16,483100%
  • Education$480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,532 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$54,535
Medicare patients
130
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$104,852
OzempicSemaglutide74$85,765
FarxigaDapagliflozin Propanediol53$62,079
TrulicityDulaglutide33$50,265
MounjaroTirzepatide27$34,764
Synjardy XrEmpagliflozin/Metformin Hcl16$19,512
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$19,022
Icosapent Ethyl29$13,730
MyrbetriqMirabegron11$8,863
SynthroidLevothyroxine Sodium59$6,476
Rosuvastatin Calcium355$4,995
Nebivolol Hcl76$3,438
Clonidine26$3,114
Ezetimibe58$2,871
Irbesartan94$1,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$1,051$124,36384 claims
Novo NordiskOzempic$2,113$85,76574 claims
Lilly USA, LLCTrulicity, Mounjaro$1,583$85,03060 claims
AstraZenecaFarxiga$2,108$62,07953 claims
GSKTrelegy Ellipta$823$19,02214 claims
Astellas Pharma US IncMyrbetriq$128$8,86311 claims
AbbVieSynthroid$1,575$6,47659 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →